SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq:AFFX) today announced that the Wellcome Trust of Great Britain has awarded to Affymetrix the second phase of its Case Control Consortium (WTCCC) project, the world’s largest-ever study of the genetics behind common diseases. The second phase will analyze the genetic information of 60,000 additional individuals, 30,000 of them with the Affymetrix® Genome-Wide Human SNP Array 6.0, plus 6,000 common controls.
